# Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

> **NCT00659373** · PHASE3 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 86 (actual)

## Conditions studied

- Breast Cancer
- Fatigue
- Sleep Disorders

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** triptorelin
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT00659373
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2014-12
- **Final completion:** 2016-04
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2016-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659373, "Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00659373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*